Guruprasad R Medigeshi
Overview
Explore the profile of Guruprasad R Medigeshi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malavige G, Medigeshi G, Sasmono R, Amaratunga C
Trends Microbiol
. 2024 Dec;
PMID: 39672746
To face the current and emerging challenges due to infectious diseases, global research communities must comprehend the challenges faced by scientists in low-income and lower-middle-income countries. Here we address pertinent...
2.
Ahmad S, Singh A, Bano N, Raza K, Singh J, Medigeshi G, et al.
Int J Biol Macromol
. 2024 May;
270(Pt 2):132332.
PMID: 38768914
Two of the deadliest infectious diseases, COVID-19 and tuberculosis (TB), have combined to establish a worldwide pandemic, wreaking havoc on economies and claiming countless lives. The optimised, multitargeted medications may...
3.
Singh J, Anantharaj A, Kumar P, Pandey R, Pandey A, Medigeshi G
J Interferon Cytokine Res
. 2024 Apr;
44(7):325-333.
PMID: 38557204
India saw a spike in COVID-19 cases in early 2023, and this wave of infection was attributed to XBB sublineages of SARS-CoV-2 Omicron variant. The impact of XBB wave was...
4.
Medigeshi G, Islam F, Lodha R
Lancet Infect Dis
. 2024 Feb;
24(5):e270-e271.
PMID: 38408459
No abstract available.
5.
Misra P, Medigeshi G, Kant S, Jaiswal A, Ahmad M, Rahman A, et al.
J Clin Med
. 2024 Feb;
13(3).
PMID: 38337457
This study was conducted with the objective of measuring the neutralizing and anti-receptor binding domain antibody levels against SARS-CoV-2 among laboratory-confirmed COVID-19 cases and exploring its long-term kinetics over a...
6.
Aggarwal C, Ahmed H, Sharma P, Reddy E, Nayak K, Singla M, et al.
Nat Med
. 2024 Feb;
30(3):670-674.
PMID: 38321219
Dengue is a global epidemic causing over 100 million cases annually. The clinical symptoms range from mild fever to severe hemorrhage and shock, including some fatalities. The current paradigm is...
7.
Manak M, Gagnon L, Phay-Tran S, Levesque-Damphousse P, Fabie A, Daugan M, et al.
Lancet Microbe
. 2024 Jan;
5(3):e216-e225.
PMID: 38278167
Background: Accurate quantitation of immune markers is crucial for ensuring reliable assessment of vaccine efficacy against infectious diseases. This study was designed to confirm standardised performance of SARS-CoV-2 assays used...
8.
Haridas V, Rajgokul K, Sadanandan S, Agrawal T, Sharvani V, Gopalakrishna M, et al.
PLoS Negl Trop Dis
. 2024 Jan;
18(1):e0011917.
PMID: 38271319
[This corrects the article DOI: 10.1371/journal.pntd.0002005.].
9.
Misra P, Singh A, Mishra B, Behera B, Patro B, Medigeshi G, et al.
PLoS One
. 2023 Dec;
18(12):e0287807.
PMID: 38079384
Repeated serological testing tells about the change in the overall infection in a community. This study aimed to evaluate changes in antibody prevalence and kinetics in a closed cohort over...
10.
Anantharaj A, Agrawal T, Shashi P, Tripathi A, Kumar P, Khan I, et al.
Commun Med (Lond)
. 2023 Oct;
3(1):148.
PMID: 37857747
Background: India is hyperendemic to dengue and over 50% of adults are seropositive. There is limited information on the association between neutralizing antibody profiles from prior exposure and viral RNA...